Treatment of anemia in patients with solid tumors receiving chemotherapy in palliative setting: usual practice versus guidelines

References

• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116 Suppl(7):11S–26S.
   PubMedGoogle Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–2306.10.1016/j.ejca.2004.06.019
   PubMed Web of Science ®Google Scholar
• Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998;25(3 Suppl 7):43–46.
   PubMed Web of Science ®Google Scholar
• Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane database Syst Rev. 2012;12:CD003407.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann Oncol. 2010;21(5):244–247.10.1093/annonc/mdq202
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Cancer- and Induced Anemia (Version 3.2014) [Internet]. National Comprehensive Cancer Network; 2014. Available from: http://williams.medicine.wisc.edu/anemia.pdf
   Google Scholar
• Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer. 2014;22(8):2197–2206.10.1007/s00520-014-2189-0
   PubMed Web of Science ®Google Scholar
• Verbeke N, Beguin Y, Wildiers H, et al. High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008). Support Care Cancer. 2012;20(1):23–28.10.1007/s00520-010-1045-0
   PubMed Web of Science ®Google Scholar
• Aapro M, Österborg A, Gascón P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron. Ann Oncol. 2012;23(8):1954–1962.10.1093/annonc/mds112
   PubMed Web of Science ®Google Scholar
• Verraes K, Prenen H. Iron deficiency in gastrointestinal oncology. Ann Gastroenterol. 2015;28(1):19–24.
   PubMed Web of Science ®Google Scholar
• Kanuri G, Sawhney R, Varghese J, et al. Iron deficiency anemia coexists with cancer related anemia and adversely impacts quality of life. PLoS One. 2016;11(9):1–11.
   Web of Science ®Google Scholar
• Henry DH, Dahl NV. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Community Oncol. 2007;4(2):95–101.10.1016/S1548-5315(11)70057-2
   Google Scholar
• Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203–212.10.1002/ajh.23628
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Schröder J, Plath M, et al. Antianemic treatment of cancer patients in german routine practice: data from a prospective cohort study – the tumor anemia registry. Anemia. 2016;2016.
   PubMedGoogle Scholar
• Seshadri T, Prince HM, Bell DR, et al. The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer. Med J Aust. 2005;182(9):453–457.
   PubMed Web of Science ®Google Scholar
• Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol. 2012;3(3):177–191.10.1177/2040620712440071
   PubMedGoogle Scholar
• Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–482.10.1093/annonc/mds338
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138(2):179–187.10.1007/s00432-011-1072-3
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer–meta-analysis based on individual patient data. Cochrane database Syst Rev. 2009;8(3):CD007303.
   Google Scholar
• Gao S, Ma J-J, Lu C. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumour Biol. 2014;35(1):603–613
   PubMedGoogle Scholar
• Glaspy J. Current status of use of erythropoietic agents in cancer patients. Semin Thromb Hemost. 2014;40(3):306–312.
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Rogak LJ, Heon N, et al. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol. 2017;143(4):735–743.10.1007/s00432-016-2335-9
   PubMed Web of Science ®Google Scholar
• Medisauskaite A, Kamau C. Prevalence of oncologists in distress: systematic review and meta-analysis. Psychooncology. 2017;26(11):1732–1740.10.1002/pon.4382
   PubMed Web of Science ®Google Scholar